Ustekinumab antibody | AbD17827_hIgG1
Antigens were coated at 5 μg/mL on a microtiter plate overnight. After washing and blocking with 5% milk powder in PBST, HRP-conjugated HCA210 (AbD17827_hIgG1; 20µL from a 2µg/mL solution in BUF049) was added. Detection was performed using the QuantaBlu™ fluorogenic peroxidase substrate.
IL-23 (1.0 µg/mL) was used as the coating antigen followed by a pre-incubated mixture of the anti-idiotypic antibody AbD17827 titrated into a constant amount of ustekinumab (0.3 µg/mL). Free ustekinumab still capable of binding to the plate was detected using Mouse anti Human IgG(Fc):HRP (MCA647P). Data is shown as the mean of three measurements.
A microtitre plate was coated over night with ustekinumab at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of Human anti ustekinumab (clone AbD17827_hIgG1). Detection was performed using HRP-conjugated ustekinumab at a concentration of 4 µg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data is shown as the mean of three measurements
Human anti Ustekinumab:HRP
Anti-ustekinumab antibody is a recombinant, high affinity anti-idiotypic antibody in full IgG1 format, ideal for bioanalytical assay development for ustekinumab and biosimilars. It is recommended as the detection antibody in PK bridging ELISA format with HCA208 or HCA209 as capture antibody.
Human anti Ustekinumab
Anti-ustekinumab antibody is a recombinant, high affinity anti-idiotypic antibody in full IgG1 format, ideal for bioanalytical assay development for ustekinumab and biosimilars. It is recommended as the detection antibody in PK bridging ELISA format with HCA208 or HCA209 as capture antibody.
- Product Type
- Monoclonal Antibody
- Clone
- AbD17827_hIgG1
- Isotype
- IgG1
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| HCA210P | E | 0.1 mg |
|
|
| HCA210 | E | 0.1 mg |
|
|
| HCA210G | E | 1 mg |
|
Human Anti-Ustekinumab Antibody, clone AbD17827_hIgG1 is a paratope specific, high affinity, anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug ustekinumab and inhibits binding to its target. The antibody can be used to measure the levels of ustekinumab and biosimilar products in bioanalytical assays.
Clone AbD17827_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator in an anti-drug antibody (ADA) assay. Additionally it can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody is recommended as the detection antibody, paired with an anti-ustekinumab antibody in monovalent Fab format as the capture antibody, clone AbD17829 (HCA208) or clone AbD18334 (HCA209).
Ustekinumab (Stelara) is a fully human monoclonal antibody drug (IgG1/kappa) that has been approved in US, Canada, and Europe for the treatment of plaque psoriasis and psoriatic arthritis. The FDA approved the medication for the treatment of moderate-severe Crohn's disease in 2016. The drug blocks interleukin IL-12 and IL-23 by binding with high affinity and specificity to the p40 subunit, preventing the binding of these two cytokines to T-lymphocytes, and thereby disrupting the proinflammatory pathway.
View a summary of all anti-ustekinumab antibodies
Clone AbD17827_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator in an anti-drug antibody (ADA) assay. Additionally it can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody is recommended as the detection antibody, paired with an anti-ustekinumab antibody in monovalent Fab format as the capture antibody, clone AbD17829 (HCA208) or clone AbD18334 (HCA209).
Ustekinumab (Stelara) is a fully human monoclonal antibody drug (IgG1/kappa) that has been approved in US, Canada, and Europe for the treatment of plaque psoriasis and psoriatic arthritis. The FDA approved the medication for the treatment of moderate-severe Crohn's disease in 2016. The drug blocks interleukin IL-12 and IL-23 by binding with high affinity and specificity to the p40 subunit, preventing the binding of these two cytokines to T-lymphocytes, and thereby disrupting the proinflammatory pathway.
View a summary of all anti-ustekinumab antibodies
Product Details
- Product Form
- Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
- Product Form
- Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Ustekinumab
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD=0.2 nM by real time, label-free molecular interaction analysis on immobilized ustekinumab.
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- Pack Size: 0.1 mgIgG concentration 0.5 mg/ml.Pack Size: 1 mgIgG concentration 1.0 mg/ml
Storage Information
- Storage
- Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Ustekinumab antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA | |||
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used in a direct ELISA or as a detection antibody in a bridging ELISA together with AbD17829 (HCA208) or AbD18334 (HCA209) as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
Protocol: PK bridging ELISA to measure free drug - ELISA
- This product may be used in a direct ELISA or as a detection antibody, in its HRP conjugated format, in a bridging ELISA together with AbD17829 (HCA208) or AbD18334 (HCA209) as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
Protocol: ADA bridging ELISA
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
| Human anti Ustekinumab | HCA208 | E | 0.1 mg |
|
|
| Human anti Ustekinumab | HCA209 | E | 0.1 mg |
|
|
| Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
| Human anti Ustekinumab | HCA208 | E | 0.1 mg |
|
|
| Human anti Ustekinumab | HCA209 | E | 0.1 mg |
|
|
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | CJ | 3 Conjugations For 400µg Antibody |
Product Specific References
References for Ustekinumab antibody
-
Kashiwagi, N. et al. (2017) Method for measuring anti-drug antibody
US Patent Application US20170315118A1
